# A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

> **NCT04847544** · PHASE2 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** ADX-629
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04847544
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-31
- **Primary completion:** 2021-10-15
- **Final completion:** 2021-10-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847544, "A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04847544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*